Abstract:Objective To assess the efficacy and safety of fluvastatin sodium extended-release tablets (fluvastatin XL) 80 mg once daily compared to fluvastatin sodium immediate-release capsules (fluvastatin IR) 40 mg twice daily in Chinese hyperlipidemic patients with moderate or high cardiovascular risk.Methods In this multi-center,randomized,double-blind,double-dummy,active-controlled,parallel-group study,after 6-week open-label treatment with fluvastatin IR 40 mg once daily,patients who did not reach their lipid goals were randomized to 12-week double-blind treatment with fluvastatin XL 80 mg once daily or fluvastatin IR 40 mg twice daily.Results (1) There were 218 patients enrolled in each group.At the study endpoint,no statistical difference was found in the mean percent change from baseline for LDL-C with-8.69％ [from (3.504 ±0.060) mmol/L to (3.153 ±0.065) mmol/L] in the fluvastatin XL group and-7.89％ [from (3.491 ±0.050) mmol/L to (3.181 ±0.060) mmol/L] in the fluvastatin IR group (P ＞ 0.05).The 95％ CI for difference between the two groups in adjusted mean percent change from baseline was (-4.70％-3.09％),which was within the pre-specified non-inferiority margin.In the fluvastatin XL group,the proportion of patients with moderate cardiovascular(CV) risk and high CV risk achieving their LDL-C treatment goals at endpoint was 50.0％ and 31.5％ respectively,while the proportion was 42.5％ and 24.5％ respectively in the fluvastatin IR group.No significant difference was found between the two groups in the proportion of patients who reached their lipid goals and the changes from baseline with other lipid parameters.(2)Similar safety profiles were observed in the two treatment groups,with 21.1％ adverse event (AE) (8.3％ study-drug related AE) in the fluvastatin XL group and 17.0％ AE (6.3％ study-drug related AE) in the fluvastatin IR group.Conclusion The efficacy of fluvastatin XL 80 mg once daily is comparable to fluvastatin IR 40 mg twice daily in Chinese hyperlipidemic patients with moderate or high cardiovascular risk and both treatments are safe and well-tolerated.

Influence of Fluvastatin on Postprandial High-Sensitivity C-reactive Protein Concentrations in Patients at High Risk of Cardiovascular Event

Fluvastatin Blunts The Effect Of A High-Fat Meal On Plasma Triglyceride And High-Sensitivity C-Reactive Protein Concentrations In Patients At High Risk For Cardiovascular Events

Effects of Different Doses of Rosuvastatin on High-sensitivity C-reactive Protein(hs-CRP) and Interleukin-6 (IL-6) in Patients with Acute Coronary Syndrome.

The effect of simvastatin on C reactive protein in patients with coronary heart disease

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

Influnence of Simvastatin on high-sensitivity C-reactive protein and fibrinogen concentrations in patients with unstable angina

Fluvastatin Improves Postprandial Vascular Inflammation Response and Fibrinolytic Dysfunction in Patients With Type 2 Diabetes Mellitus

Effect of Fluvastatin and Valsartan, Alone and in Combination, on Postprandial Vascular Inflammation and Fibrinolytic Activity in Patients with Essential Hypertension.

Effect of Fluvastatin and Valsartan Combination Treatment on Postprandial Fibrinolytic Dysfunction in Patients with Essential Hypertension

Influence of Short-Term Treatment with Simvastatin 40 Mg on Plasma Concentration of High-Sensitivity C-reactive Protein in Patients with Unstable Angina Pectoris

[The Effect of Early Fluvastatin Therapy on Inflammatory Factors in Acute Coronary Syndrome].

The Effect of Different Doses of Fluvastatin on Inflammatory Markers in the Early Phase of Acute Coronary Syndrome

Effect and Risk Factors of Pitavastatin on High Sensitivity C-reactive Protein in Patients with Hypercholesterolemia: a Multilevel Models Analysis

Efficacy and safety of fluvastatin extended-release tablets in Chinese patients with hyperlipidemia: a multi-center, randomized, double-blind, double dummy, active-controlled, parallel-group study

Effect of Atorvastatin Versus Rosuvastatin on Levels of Serum Lipids, Inflammatory Markers and Adiponectin in Patients with Hypercholesterolemia

Influence of intervention with statins on the levels of cholesterol and inflammatory markers on non-ST-elevation acute coronary syndrome patients

Effect of Valsartan on Postprandial Plasma Inflammatory Factors in Patients with Essential Hypertension

Effects of Fluvastatin Therapy on Serum Interleukin-18 and Interleukin-10 Levels in Patients with Acute Coronary Syndrome

The Effect of Simvastatin and Pravastatin on Serum Lipid and C Reactive Protein in Patients with Acute Coronary Syndrome

Short-term Effect of Simvastatin on Serum C-reactive Protein of Hyperlipidemia Patients

EFFECT OF AGGRESSIVE LIPID-LOWERING ON RESTENOSIS IN PATIENTS WITH SUCCESSFUL CORONARY STENT IMPLANTATION